Simulations Plus Positioned to Capitalize on FDA's Streamlined Nonclinical Safety Guidance with Advanced Mechanistic and Model-Informed Solutions

Stock Information for Simulations Plus Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Simulations Plus Inc.

Simulations Plus Reports Fourth Quarter and Fiscal 2025 Financial Results
INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation of Simulations Plus, Inc. (NASDAQ: SLP) and Encourages Investors with Substantial Losses to Contact the Firm
INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation of Simulations Plus, Inc. (NASDAQ: SLP) and Encourages Investors with Substantial Losses to Contact the Firm
SLP INVESTOR REMINDER: Simulations Plus, Inc. Investors may have been Affected by Fraud -- Contact BFA Law if You Suffered Losses
SIMULATIONS PLUS INVESTIGATION: Bragar Eagel & Squire, P.C. Urges Simulations Plus Investors to Contact the Firm Regarding Their Rights
SLP STOCK DROP ALERT: Simulations Plus, Inc. 26% Stock Drop Triggers Securities Class Action Investigation, Investors Urged to Contact BFA Law
SLP STOCK LOSS NOTICE: Simulations Plus, Inc. Investors are Notified they may have been Affected by Fraud and are Urged to Contact BFA Law
Rosen Law Firm Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.